Encouraging Results from a First-in-Human Phase 1 Clinical Trial of IAVI's Lassa Vaccine Candidate Published in New England Journal of Medicine

One dose elicits robust and long-lasting immune responses in healthy adults in the U.S. and Liberia Key takeaways: IAVI's ...